

ARCA biopharma, Inc.
Form 3
February 05, 2009

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â ZABRISKIE JOHN L		(Month/Day/Year)	ARCA biopharma, Inc. [ABIO]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
		01/27/2009		
207 JUNIPER COURT			(Check all applicable)	
(Street)			<input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below)	
BASALT,Â COÂ 81621			6. Individual or Joint/Group Filing(Check Applicable Line)	
(City)	(State)	(Zip)	<input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	29,180	I	See Footnote ⁽¹⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable Expiration Date	Title Amount or Number of			

Edgar Filing: ARCA biopharma, Inc. - Form 3

				Shares		(I) (Instr. 5)	
Option to Purchase Common Stock	Â (2)	08/03/2015	Common Stock	3,887	\$ 0.6	D	Â
Option to Purchase Common Stock	Â (3)	08/03/2016	Common Stock	5,694	\$ 0.9	D	Â
Option to Purchase Common Stock	Â (4)	02/02/2017	Common Stock	4,174	\$ 1.68	D	Â
Option to Purchase Common Stock	Â (5)	05/02/2018	Common Stock	4,174	\$ 1.86	D	Â
Option to Purchase Common Stock	Â (6)	01/22/2019	Commprn Stock	1,786	\$ 5.57	D	Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ZABRISKIE JOHN L 207 JUNIPER COURT BASALT, CO 81621	Â X	Â	Â	Â

Signatures

Patrick Wheeler, attorney
in fact 02/05/2009

__Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

These shares are owned directly by Lansing Brown Investments, LLC. Dr. Zabriskie, one of ARCA's current directors, is the President of

(1) Lansing Brown Investments, LLC. Dr. Zabriskie has shared voting and dispositive powers over the shares held by Lansing Brown Investments, LLC. He disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in them

(2) The options vested as to 971 shares on May 4, 2006; and continue to vest by 242 shares at the end of each quarter thereafter.

(3) The options vested as to 1,423 shares on August 3, 2007; and continue to vest by 355 shares at the end of each quarter thereafter.

(4) The options vested as to 1,043 shares on February 2, 2008; and continue to vest by 260 shares at the end of each quarter thereafter.

(5) The options vest as to 1,043 shares at the end of each quarter following grant date.

(6) The options are immediately exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.